BMO Capital Upgrades Bristol-Myers Squibb Co. (BMY) to Market Perform Citing More Balanced Risk/Reward

April 27, 2018 4:10 AM

BMO Capital upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Underperform to Market Perform with a price target of $47.00.Analyst Alex ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found